RECENT NEWS

Visit the WFH News page to find out more about the events and developments that are making a difference today.

19th NTGT workshop marks 30 years of scientific innovation

19th NTGT workshop marks 30 years of scientific innovation

This November, the World Federation of Hemophilia (WFH) will mark 30 years of scientific innovation with the 19th New Technology and Gene Therapy (NTGT) Workshop in Montreal, Canada. Experts from around the world will come to the city on November 12 to 13, 2026 to explore the latest developments in hemophilia treatment and research.

Also available in: Español

Over the past three decades, the New Technology and Gene Therapy (NTGT) Workshop has provided a valuable opportunity for leading researchers and clinicians to exchange knowledge, discuss emerging developments, and consider the future of care for people with hemophilia and other inherited bleeding disorders.

Initially hosted by the National Bleeding Disorders Foundation (NBDF), the workshop has evolved alongside some of the most significant advances in the field. Building on this legacy, the WFH assumed leadership of the workshop with the 18th edition in 2024.  The 2026 meeting marks the second consecutive edition convened by the WFH and reflects the federation’s ongoing commitment to fostering collaboration and innovation across the global bleeding disorders community.

The treatment landscape today is dramatically different from what it was when the first workshop took place in 1996. At that time, treatment options for hemophilia were far more limited than they are today. A decade later, the first liver-directed gene therapy trial in hemophilia B had begun, and, by 2017, non-factor therapies were reshaping prophylactic care. Today, gene therapy is commercially available in some countries; this is just another step in the scientific journey that this workshop has followed.  

The 2026 program will bring together experts in hematology, immunology, clinical research, biotechnology, and patient advocacy to examine the latest developments in new protein technologies, adeno-associated virus (AAV) gene therapies and other delivery systems, gene editing, and novel therapies for other bleeding disorders. The workshop will also feature a dedicated discussion on clinical trial participation and patient enrolment, exploring factors that influence enrolment decisions from both patient and investigator perspectives.

As the global research community continues to push the boundaries of treatment development, the 19th edition of the NTGT will serve as a forum for scientific discussion, knowledge exchange, and critical examination of the opportunities and challenges shaping the future of bleeding disorders care.

Through initiatives such as the New Technology and Gene Therapy (NTGT) Workshop , the WFH remains committed to supporting collaboration, advancing knowledge, and helping drive progress toward a future in which people with bleeding disorders everywhere can benefit from the latest scientific breakthroughs.

The 19th WFH New Technology and Gene Therapy Workshop is supported by:

  • Visionary partners: Pfizer
  • Collaborating partner: Regeneron, Roche, Sobi
  • With additional thanks to: Metagenomi

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.